MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment

MGI: A World-Leading Innovator in Gene Sequencing and Life Science

MGI, a world-leading innovator in gene sequencing and life science, is thrilled to announce that its DNBSEQ-T20×2 ("T20") gene sequencing platform has been awarded the prestigious Globee® for Medical Equipment in the 15th Annual 2023 Golden Bridge Business and Innovation Awards®. This award is a testament to MGI's commitment to pushing the boundaries of technology advancements and making significant contributions to the genetic industry.

The Golden Bridge Awards: Recognizing Visionaries and Innovators

The Golden Bridge Awards, a global recognition platform for business practices, is renowned for organizing world-class business awards programs and business ranking lists. The awards honor visionaries, innovators, and leaders who have made significant contributions in various domains of business and technology. The Golden Bridge Awards are a symbol of excellence and recognition for those who are reshaping their respective industries through innovative business practices.

MGI's Cutting-Edge Technology Advancements and Contributions

The Golden Bridge Awards carefully select experienced judges from diverse industries and backgrounds to conduct a comprehensive evaluation of the entries. This ensures that the award truly reflects the outstanding achievements and contributions of the winners in their respective fields. Among the other award winners are Amazon, IBM, and Meta, which have also been honored for their innovative business practices. This is the second time MGI has won the Golden Bridge Awards, symbolizing the global recognition of MGI's cutting-edge technology advancements and significant contributions to the life science industry.

MGI's T20*: An Ultra-High-Throughput Gene Sequencer

Launched in February 2023, MGI's T20* gene sequencer is a groundbreaking innovation in the field of gene sequencing. It is designed to improve the efficiency of our sequencing platform for even faster and higher throughput sequencing. This makes sequencing-based health monitoring and disease prevention at the molecular level affordable for all. The T20* is a testament to MGI's commitment to leading innovation in the genetic industry and reshaping healthcare outcomes.

T20*'s Impact on the Genetic Industry and Healthcare

T20* successfully reduces the unit cost of genome sequencing to sub $100, becoming an important driving force for the expansion of the global genetic industry. This will accelerate the progress of human genome understanding and medical applications, and fundamentally reshape the industry ecology. The T20* is not just a gene sequencer; it is a revolutionary tool that is making genome sequencing accessible and affordable, thereby promoting precision medicine and disease prevention.